Skip to main content
Fig. 7 | Stem Cell Research & Therapy

Fig. 7

From: A novel therapeutic management for diabetes patients with chronic limb-threatening ischemia: comparison of autologous bone marrow mononuclear cells versus allogenic Wharton jelly-derived mesenchymal stem cells

Fig. 7

Diabetic patients with CTLI conserved their limbs after the treatment with auto-BM-MNC or allo-WJ-MSCs. Amputation-free survival analysis showed that patients with CLTI treated with auto-BM-MNC and allo-WJ-MSCs conserved 100% of their limbs during 12 months of the follow-up compared to the placebo group, where 60% of participants underwent limb amputation at different times. Auto-BM-MNC, autologous bone marrow mononuclear cell and allo-WJ-MSCs, allogenic Wharton jelly-derived mesenchymal stem cells

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512